Somatic cells with innate potential for pluripotency
View Patent ↗Aspects of the present invention are drawn to compositions of somatic cells with innate potential for pluripotency (SCIPP). SCIPP have the capacity to differentiate into functional derivatives of each of the major germ layers (i.e., ectodermal, endodermal and mesodermal). Also provided are methods and kits for identifying and isolating the somatic cells from a subject as well as for employing SCIPP for research or therapeutic purposes.
1. An isolated population of cells,
wherein at least 8% of the cells are Somatic Cells with an Innate Potential for Pluripotency (SCIPP),
wherein the SCIPP are CD73 + /CD90 − /CD45 − cells, wherein CD45 is a Lineage marker, and
wherein the SCIPP cells are bound by an anti-CD73 antibody,
wherein the anti-CD73 antibody is immobilized on a solid support or is conjugated to a detectable label.
2. The isolate population of cells of claim 1 , wherein the anti-CD73 antibody is immobilized on a solid support.
3. The isolate population of cells of claim 2 , wherein the solid support is a bead, plate or a membrane.
4. The isolate population of cells of claim 1 , wherein the anti-CD73 antibody is conjugated to a detectable label.
5. The isolate population of cells of claim 4 , wherein the detectable label comprises a fluorescent label.
6. The isolate population of cells of claim 1 , wherein the SCIPP cells are negative for a Lineage marker selected from the group consisting of: CD2, CD3, CD16, CD31, CD64 and CD140b.
7. The isolate population of cells of claim 1 , wherein the SCIPP are derived from disease-free mammary tissue.
8. The isolate population of cells of claim 1 , wherein the SCIPP are human SCIPP.
9. The isolate population of cells of claim 1 , wherein at least 50% of the cells in the isolated population are SCIPP.
10. An isolated population of cells,
wherein at least 8% of the cells are Somatic Cells with an Innate Potential for Pluripotency (SCIPP),
wherein the genetically modified SCIPP are CD73 + /CD90 − /CD45 − cells, wherein CD45 is a Lineage marker, and
wherein the SCIPP cells are genetically modified.
11. The isolated population of cells of claim 10 , wherein the SCIPP cells are negative for a Lineage marker selected from the group consisting of: CD2, CD3, CD16, CD31, CD64 and CD140b.
12. The isolated population of cells of claim 10 , wherein the SCIPP are derived from disease-free mammary tissue.
13. The isolated population of cells of claim 10 , wherein the SCIPP are human SCIPP.
14. The isolate population of cells of claim 10 , wherein at least 50% of the cells in the isolated population are SCIPP.